ECSP17034829A - Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf - Google Patents

Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf

Info

Publication number
ECSP17034829A
ECSP17034829A ECIEPI201734829A ECPI201734829A ECSP17034829A EC SP17034829 A ECSP17034829 A EC SP17034829A EC IEPI201734829 A ECIEPI201734829 A EC IEPI201734829A EC PI201734829 A ECPI201734829 A EC PI201734829A EC SP17034829 A ECSP17034829 A EC SP17034829A
Authority
EC
Ecuador
Prior art keywords
high concentration
protein
solution containing
antibody
vegf antibody
Prior art date
Application number
ECIEPI201734829A
Other languages
English (en)
Spanish (es)
Inventor
Boring Charles
Alani Laman
S R L 1855
Kulshreshtha Alok
Cropscience Limited Bayer
Zeng Yuhong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17034829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP17034829A publication Critical patent/ECSP17034829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ECIEPI201734829A 2014-11-07 2017-06-05 Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf ECSP17034829A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
ECSP17034829A true ECSP17034829A (es) 2019-02-28

Family

ID=54697654

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201734829A ECSP17034829A (es) 2014-11-07 2017-06-05 Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf

Country Status (24)

Country Link
US (5) US10689438B2 (OSRAM)
EP (2) EP3215122B1 (OSRAM)
JP (6) JP6753848B2 (OSRAM)
KR (4) KR20170082526A (OSRAM)
CN (4) CN107635580A (OSRAM)
AU (6) AU2015342818B2 (OSRAM)
BR (2) BR112017008093A2 (OSRAM)
CA (1) CA2966646A1 (OSRAM)
CL (2) CL2017001115A1 (OSRAM)
CO (1) CO2017004596A2 (OSRAM)
EA (1) EA201790989A1 (OSRAM)
EC (1) ECSP17034829A (OSRAM)
GT (1) GT201700096A (OSRAM)
IL (5) IL251642B (OSRAM)
MX (3) MX383399B (OSRAM)
MY (2) MY183807A (OSRAM)
NZ (1) NZ730821A (OSRAM)
PE (1) PE20170780A1 (OSRAM)
PH (3) PH12021550147A1 (OSRAM)
RU (1) RU2722643C2 (OSRAM)
SG (3) SG10201913565RA (OSRAM)
TN (1) TN2017000128A1 (OSRAM)
TW (4) TWI738632B (OSRAM)
WO (2) WO2016073915A1 (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CA2727992C (en) 2008-06-25 2017-10-17 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting tnf.alpha.
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
BR112017014376A2 (en) 2015-01-28 2018-05-02 Pfizer Inc. stable aqueous formulation of vascular endothelial growth antifactor (vegf) antibodies and use
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
AU2016362129A1 (en) 2015-12-04 2018-06-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
AU2017324983B2 (en) * 2016-09-07 2025-03-20 Saksin Lifesciences Pvt Ltd Synthetic antibodies against VEGF and their uses
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
JOP20190103B1 (ar) 2016-11-18 2023-09-17 Astellas Pharma Inc شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN109562166B (zh) * 2017-04-28 2021-04-02 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
MX2020003041A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
CN111433223B (zh) * 2017-11-29 2024-08-27 诺和诺德A/S（股份有限公司） 抗甲状腺素运载蛋白单克隆抗体的冻干制剂
SMT202200374T1 (it) 2017-11-30 2022-11-18 Regeneron Pharma Uso di un antagonista del vegf per trattare disturbi angiogenici dell’occhio
JP7005772B2 (ja) * 2018-02-06 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー 眼科疾患の処置
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US20210017266A1 (en) * 2018-03-16 2021-01-21 Novartis Ag Methods for treating ocular diseases
MX2020009935A (es) * 2018-03-23 2021-01-08 Abbvie Deutschland Formulaciones acuosas y estables de anticuerpos anti-tau.
EP3775267A4 (en) * 2018-04-10 2022-05-18 Askgene Pharma, Inc. NOVEL ANGIOPOIETIN-2, VEGF DUAL ANTAGONISTS
KR20210021299A (ko) 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
WO2019221269A1 (ja) 2018-05-17 2019-11-21 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CN117752825A (zh) * 2018-10-10 2024-03-26 安斯泰来制药株式会社 含有标记部-抗人抗体Fab片段复合物的药物组合物
IL281717B2 (en) * 2018-10-29 2025-07-01 Hoffmann La Roche Antibody formulation
EP3826682A4 (en) 2018-11-07 2021-11-17 Applied Molecular Transport Inc. CHOLIX-DERIVED MEDIA FOR ORAL HETEROLOGICAL LOADING ADMINISTRATION
JOP20210152A1 (ar) * 2018-12-18 2023-01-30 Novartis Ag صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
TW202532428A (zh) 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
CN114786731A (zh) * 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
KR20220149690A (ko) * 2020-03-04 2022-11-08 상하이 헨리우스 바이오테크, 인크. 베바시주맙을 포함하는 약물 조제용 제제
CN113698478B (zh) * 2020-05-21 2025-11-18 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
CR20230009A (es) 2020-07-16 2023-01-25 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
TW202313095A (zh) * 2021-05-17 2023-04-01 美商再生元醫藥公司 用於治療血管新生眼疾之延長、高劑量vegf拮抗劑方案
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
JP2025529465A (ja) * 2022-09-16 2025-09-04 チールー ファーマシューティカル カンパニー、リミテッド 安定な高濃度自己緩衝医薬組成物
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2324848A3 (en) * 2004-10-21 2011-09-14 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2432155C3 (ru) * 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
CA2727992C (en) 2008-06-25 2017-10-17 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting tnf.alpha.
KR102095257B1 (ko) * 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
CN105153300A (zh) 2008-06-30 2015-12-16 艾斯巴技术-诺华有限责任公司 官能化的多肽
PL2515941T3 (pl) 2009-12-21 2020-04-30 F. Hoffmann-La Roche Ag Preparat farmaceutyczny zawierający bewacyzumab
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
MX385629B (es) * 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
US20130004484A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
ES2687245T3 (es) * 2011-10-20 2018-10-24 Esbatech - A Novartis Company Llc Anticuerpo estable de unión a antígenos múltiples
US20130316001A1 (en) 2012-05-03 2013-11-28 Kala Pharmaceuticals, Inc. Particles, compositions and methods for ophthalmic and/or other applications
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
BR112016029864A2 (pt) * 2014-06-17 2017-08-22 Clearside Biomedical Inc métodos e dispositivos para tratamento de desordens oculares posteriores.
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US20210017266A1 (en) 2018-03-16 2021-01-21 Novartis Ag Methods for treating ocular diseases
JOP20210152A1 (ar) 2018-12-18 2023-01-30 Novartis Ag صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf

Also Published As

Publication number Publication date
MY193913A (en) 2022-11-01
TWI761959B (zh) 2022-04-21
CN114081951A (zh) 2022-02-25
US20160340420A1 (en) 2016-11-24
CL2017001115A1 (es) 2018-01-26
PH12021550147A1 (en) 2023-01-23
JP2017538674A (ja) 2017-12-28
CO2017004596A2 (es) 2017-08-31
KR102588846B1 (ko) 2023-10-16
EP3215122B1 (en) 2025-08-13
CA2966758A1 (en) 2016-05-12
CN120938921A (zh) 2025-11-14
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
IL283561B (en) 2022-01-01
PH12017500844B1 (en) 2021-05-05
AU2020244614B2 (en) 2023-06-01
MX383808B (es) 2025-03-14
IL280087A (en) 2021-03-01
TW202146049A (zh) 2021-12-16
EA201790989A1 (ru) 2017-09-29
US20180298092A1 (en) 2018-10-18
PE20170780A1 (es) 2017-07-04
KR102724014B1 (ko) 2024-10-31
EP3215123A1 (en) 2017-09-13
SG11201702954XA (en) 2017-05-30
CN106999581A (zh) 2017-08-01
AU2018278870A1 (en) 2019-01-03
BR112017008660A2 (pt) 2017-12-26
JP2020079242A (ja) 2020-05-28
TW202103735A (zh) 2021-02-01
US12049495B2 (en) 2024-07-30
AU2018278870B2 (en) 2020-05-28
AU2018274882B2 (en) 2020-07-09
MY183807A (en) 2021-03-16
JP2022141923A (ja) 2022-09-29
JP2017534638A (ja) 2017-11-24
SG10201913565RA (en) 2020-02-27
US10035850B2 (en) 2018-07-31
GT201700096A (es) 2019-10-10
RU2020114917A3 (OSRAM) 2022-01-17
US20160130337A1 (en) 2016-05-12
AU2015342815A1 (en) 2017-05-11
WO2016073915A1 (en) 2016-05-12
TWI738632B (zh) 2021-09-11
AU2018274882A1 (en) 2018-12-20
US11098110B2 (en) 2021-08-24
MX2021006768A (es) 2021-07-15
AU2020220210A1 (en) 2020-10-01
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
RU2017119647A (ru) 2018-12-07
EP3215122C0 (en) 2025-08-13
JP7080263B2 (ja) 2022-06-03
WO2016073918A1 (en) 2016-05-12
IL265497A (en) 2019-05-30
AU2020244614A1 (en) 2020-11-05
MX2017005875A (es) 2017-06-26
IL280087B (en) 2022-02-01
JP6667519B2 (ja) 2020-03-18
BR112017008093A2 (pt) 2018-03-13
US20210340242A1 (en) 2021-11-04
TWI705827B (zh) 2020-10-01
KR20170076781A (ko) 2017-07-04
KR20170082526A (ko) 2017-07-14
IL251642A0 (en) 2017-06-29
RU2017119647A3 (OSRAM) 2019-05-29
IL251696A0 (en) 2017-06-29
TW201625221A (zh) 2016-07-16
CA2966646A1 (en) 2016-05-12
CN107635580A (zh) 2018-01-26
IL265497B (en) 2021-06-30
IL283561A (en) 2021-07-29
IL251642B (en) 2021-02-28
MX383399B (es) 2025-03-13
CL2017001117A1 (es) 2018-01-26
TWI806150B (zh) 2023-06-21
TN2017000128A1 (en) 2018-10-19
EP3215122A1 (en) 2017-09-13
JP2020193212A (ja) 2020-12-03
RU2020114917A (ru) 2020-05-22
US12371481B2 (en) 2025-07-29
MX2017005874A (es) 2017-06-26
PH12017500843A1 (en) 2017-10-30
US20200270336A1 (en) 2020-08-27
AU2020220210B2 (en) 2022-01-20
KR20230066649A (ko) 2023-05-16
PH12017500844A1 (en) 2017-10-30
AU2015342818B2 (en) 2019-01-03
TW201625306A (zh) 2016-07-16
NZ730821A (en) 2019-11-29
RU2722643C2 (ru) 2020-06-02
JP2025004075A (ja) 2025-01-14
KR20240161204A (ko) 2024-11-12
JP6753848B2 (ja) 2020-09-09

Similar Documents

Publication Publication Date Title
ECSP17034829A (es) Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CO7111300A2 (es) Formulación de anticuerpos
AR107014A1 (es) Formulación farmacéutica acuosa
CL2018003178A1 (es) Composición farmacéutica
BR112016026811A2 (pt) formulação de anticorpo
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
CL2021001587A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf